Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.47 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.44 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2981479 | 0.94 | HDAC6 (0.58) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL2981054 | 0.93 | HDAC6 (0.48) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL8259812 | 0.89 | HDAC6 (0.49) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL2976157 | 0.87 | HDAC6 (0.59) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL2981744 | 0.87 | HDAC6 (0.51) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL2969861 | 0.87 | HDAC1 (0.44) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL2976382 | 0.87 | HDAC6 (0.58) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL2980516 | 0.85 | HDAC1 (0.56) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL2978769 | 0.85 | HDAC6 (0.56) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL5316903 | 0.84 | MAP3K11 (0.51) | HDAC6HDAC1MAP3K11TNIKALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | claimed |
| US-20060199829-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. | 2006-09-07 | — | — | US | claimed |
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1851219-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | Miikana Therapeutics, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060199829-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006088949-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006088949-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199829-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | HDAC6 11/4885HDAC1 1/4885HDAC3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.